There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

The report provides a detailed analysis of the current myelodysplastic syndrome marketed drugs and late-stage pipeline drugs.

A panelist highlights that updated COMMANDS trial data demonstrate luspatercept’s robust efficacy in erythropoiesis-stimulating agent–naive patients with low-risk myelodysplastic syndrome—achieving ...

Pune: A 70-year-old woman from Mumbai, misdiagnosed with myelodysplastic syndromes (MDS), a type of blood cancer specifically ...

A panelist emphasizes that recent real-world retrospective data from 103 first-line luspatercept-treated patients closely align with, and even slightly exceed, COMMANDS trial results—demonstrating ...

It took a misplaced elbow, a quirk of Los Angeles geography and some whistling from his wife to produce one of television’s most memorable melodies.

I’ve survived rare blood cancer for 15 years, but the lasting side effects have taken a toll — even so, I still find purpose, ...

The Little Rock community gathered for Rozanne Pumphrey, a mother and grandmother who is battling myelodysplastic syndrome.

Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, and their five-year survival rate is around 30%. MDS are characterized ...

Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with ...

Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later ...